Bristol-based digital health company Neuronostics has been celebrated as Most Transformative Healthtech Company at the OBN Awards 2025.

The team behind BioEP™, Neuronostics’ digital biomarker, is revolutionising epilepsy diagnosis by revealing patterns in EEG data that would otherwise go unnoticed. This additional insight supports clinicians in making more confident, data-driven decisions, helping patients receive the right care sooner.

Neuronostics has been a member of SETsquared Bristol since 2021, working with the programme to access business support and guidance as they develop and scale their technology.

Anne Hyland, Chair of Neuronostics, said:
“BioEP enhances traditional EEGs, giving clinicians clearer information and strengthening the diagnostic pathway. It’s exciting to see the impact of our work recognised in this way.”

The award comes after a year of remarkable milestones, including a partnership with US EEG services leader Stratus and a win at the US Epilepsy Foundation’s Shark Tank Competition. With regulatory approvals in the UK and UAE, Neuronostics is now working towards expansion into new international markets.

About Neuronostics
Based in Bristol, Neuronostics develops digital health solutions that uncover hidden features in EEG recordings to support faster, more accurate clinical decisions. Find out more at www.neuronostics.com.

Find out about SETsquared Bristol’s incubation programme.